Peptide Half-Lives: The Math Behind Weekly Protocols

Dosing frequency for a peptide is not a stylistic choice. It is a direct consequence of how quickly the molecule is cleared from circulation, how that clearance follows first-order kinetics, and what plasma concentration the researcher is attempting to maintain. Peptides with elimination half-lives measured in minutes demand daily or twice-daily administration to sustain exposure, while acylated or Fc-fused analogs with half-lives measured in days tolerate weekly or even bi-weekly protocols. The math is not optional, and it is the same math clinical pharmacologists use when designing Phase I dose-ranging studies.

First-order elimination: the governing equation

Most peptides, like most small molecules, are cleared from plasma by first-order kinetics. This means a constant fraction — not a constant amount — of the drug is eliminated per unit time. The governing equation is straightforward:

C(t) = C₀ · e^(-kt)

Where C(t) is the plasma concentration at time t, C₀ is the concentration immediately after absorption, and k is the elimination rate constant. The half-life (t½) is related to k by t½ = 0.693 / k. Because the fraction eliminated is constant, the absolute amount cleared depends on how much is present: a researcher who doubles the dose does not shorten the half-life, only raises the starting concentration.

This has a consequence that non-specialists sometimes miss. After one half-life, 50% of the peak concentration remains. After two, 25%. After three, roughly 12.5%. After four, about 6%. After five half-lives, approximately 97% of a single dose has been eliminated, which is the convention pharmacologists use when declaring a compound "functionally cleared." The same convention determines when steady state is reached on a repeated-dose schedule.

For peptides, the elimination rate is typically dominated by proteolytic degradation in plasma and tissues, renal filtration for smaller sequences (under roughly 5 kDa), and receptor-mediated clearance for ligands that bind high-affinity receptors. Modifications such as PEGylation, lipidation (fatty-acid acylation, as in semaglutide), or fusion to Fc domains or albumin-binding motifs are specifically designed to slow these clearance pathways and extend t½.

Why half-life varies by orders of magnitude

Endogenous peptides are generally short-lived. Native GLP-1, for example, has a reported plasma half-life of approximately one to two minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4). Native growth hormone-releasing hormone (GHRH) has a half-life of several minutes. Native ghrelin is cleared within roughly 30 minutes. These values reflect the signaling role of the molecules: the body uses rapid degradation to keep pulsatile, tightly regulated endocrine signals from persisting past their window of usefulness.

Synthetic analogs engineered for research and clinical use deliberately extend this window. A few well-characterized examples:

• CJC-1295 with DAC (drug affinity complex): a GHRH analog with an albumin-binding maleimide group. Reported plasma half-life in published studies is approximately 6–8 days, enabling weekly or twice-weekly dosing in research protocols.
• Semaglutide: a lipidated GLP-1 analog. Half-life reported at approximately 160–170 hours (about one week), which is the pharmacokinetic basis for once-weekly subcutaneous administration.
• Tesamorelin: a stabilized GHRH analog. Reported half-life is in the range of 30–40 minutes for the parent peptide, though its biological effect persists longer due to downstream hormonal cascades.
• BPC-157: reported plasma half-life is short — minutes, in the few rodent pharmacokinetic studies available — though tissue-level effects and the clinical relevance of systemic exposure remain under investigation.
• Ipamorelin: a ghrelin-mimetic secretagogue with a reported half-life of roughly two hours, requiring multiple daily administrations to sustain exposure.

The three-orders-of-magnitude spread between native GLP-1 (minutes) and semaglutide (a week) is not a trivial detail. It is the single variable that determines whether a protocol calls for pre-meal injections or a single weekly dose.

Calculating steady state

When a peptide is administered at a fixed interval that is short relative to its half-life, plasma concentration accumulates over successive doses until input equals output. This plateau is called steady state, and the useful rule is that steady state is reached after approximately 4–5 half-lives of repeated dosing, regardless of the dose size or interval (assuming first-order kinetics hold).

The average steady-state concentration (Css,avg) for repeated dosing is given by:

Css,avg = (F · Dose) / (CL · τ)

Where F is bioavailability (fraction of the dose reaching systemic circulation), CL is clearance, and τ is the dosing interval. Equivalently, using half-life:

Css,avg = (1.44 · F · Dose · t½) / (Vd · τ)

Where Vd is the volume of distribution. The practical point researchers extract from these equations is the accumulation ratio — the ratio of steady-state peak to first-dose peak — which depends only on the ratio of half-life to dosing interval:

Accumulation ratio ≈ 1 / (1 − e^(-0.693 · τ / t½))

If τ equals t½ (dosing once per half-life), the accumulation ratio is 2: steady-state peak is twice the first-dose peak. If τ equals two half-lives, accumulation ratio is about 1.33. If τ is less than one half-life, accumulation climbs quickly — which is why short-interval dosing of long half-life compounds requires dose reduction, or plasma levels will keep rising for weeks before plateauing.

This also explains why loading doses exist. If a researcher wants to reach steady state without waiting five half-lives — which for semaglutide would be roughly five weeks — a larger initial dose can be used to raise plasma concentration directly to the target plateau. The math for a loading dose is simply the target Css multiplied by Vd, divided by F.

A worked example

Consider a hypothetical acylated peptide analog with the following characteristics, chosen to illustrate the math rather than to represent any specific compound:

• Elimination half-life: 72 hours (3 days)
• Volume of distribution: 10 L
• Bioavailability (subcutaneous): 80%
• Dosing interval: every 7 days (once weekly)
• Dose: 1 mg per administration

The elimination rate constant k = 0.693 / 72 = 0.00963 per hour. The clearance CL = k · Vd = 0.00963 × 10 = 0.0963 L/hour, or about 2.31 L/day.

Average steady-state concentration:

Css,avg = (0.80 · 1 mg) / (2.31 L/day · 7 days) = 0.8 / 16.17 = 0.0495 mg/L ≈ 49.5 ng/mL

Accumulation ratio for τ/t½ = 168/72 = 2.33:

R ≈ 1 / (1 − e^(-0.693 · 2.33)) = 1 / (1 − e^(-1.62)) = 1 / (1 − 0.198) = 1 / 0.802 ≈ 1.25

So steady-state peak is roughly 25% higher than the first-dose peak — modest accumulation. Steady state is reached after approximately 4–5 half-lives, or 12–15 days — meaning the second or third weekly dose produces concentrations near the eventual plateau.

Now consider what happens if the same compound is dosed daily instead of weekly at the same 1 mg per dose. τ/t½ = 24/72 = 0.33, and the accumulation ratio becomes:

R ≈ 1 / (1 − e^(-0.693 · 0.33)) = 1 / (1 − e^(-0.229)) = 1 / (1 − 0.795) = 1 / 0.205 ≈ 4.87

Steady-state peak is now nearly five times the first-dose peak, and Css,avg rises to roughly 347 ng/mL — a seven-fold increase in average exposure for a seven-fold increase in weekly dose. Linear, as first-order kinetics predicts, but the peak-to-trough ratio has collapsed from roughly 2:1 on weekly dosing to near-flat on daily dosing. The choice between the two is not about total dose; it is about desired profile.

Why some peptides tolerate weekly dosing and others do not

The question is not only whether steady state can be achieved but whether the peak-to-trough ratio is acceptable. For compounds with short half-lives — ipamorelin, tesamorelin, native GHRH analogs without DAC — weekly administration would produce a single brief peak followed by six days of essentially zero plasma concentration. For receptor systems that desensitize on sustained exposure, this pulsatility may be desirable; for receptor systems that require continuous occupancy to produce the downstream effect, it is not.

A few factors determine whether a long dosing interval is pharmacologically sensible:

• Receptor pharmacology: GLP-1 receptors tolerate continuous agonism well at engineered concentrations, which is why once-weekly semaglutide works. Growth hormone secretagogue receptors, by contrast, desensitize relatively quickly, which is part of why secretagogue protocols often use pulsed rather than continuous exposure.
• Therapeutic window: compounds with narrow windows between effective and adverse exposure require dosing intervals that minimize peak-to-trough variation, which generally means τ well below t½.
• Half-life of the downstream effect: the pharmacokinetic half-life of the peptide is not always the pharmacodynamic half-life of its effect. Tesamorelin has a short plasma t½ but stimulates IGF-1 production for considerably longer, because IGF-1 itself has a half-life of roughly 15 hours and is produced continuously from hepatocytes exposed to the GH pulse.

This gap between PK and PD is where simple half-life math stops being sufficient and where researchers turn to compartmental modeling, receptor occupancy estimates, and downstream biomarker tracking.

Common errors researchers make with the math

Three mistakes recur in peptide dosing discussions, including in protocols circulated informally:

1. Confusing terminal half-life with effect duration. A compound with a 30-minute plasma half-life can produce biological effects lasting days if it triggers a hormonal cascade or induces gene expression. Plasma t½ governs plasma concentration, not biological outcome.
2. Assuming dose-proportionality holds at all doses. First-order kinetics breaks down when clearance pathways saturate — enzyme-mediated degradation, receptor-mediated uptake, renal transporters. At high doses, half-life can appear to lengthen (zero-order or Michaelis-Menten regimes), and simple accumulation math fails.
3. Ignoring injection-site absorption kinetics. Subcutaneous peptides absorb over hours, not instantaneously. For short-half-life peptides, the absorption rate can become the rate-limiting step, flattening the peak and making the apparent half-life longer than the true elimination half-life. This is formally described as flip-flop kinetics and is common with depot or lipidated formulations.

Each of these can be caught by checking published pharmacokinetic data rather than extrapolating from a single number.

What to read next

• Compartmental modeling (one-compartment vs. two-compartment) and when the simpler first-order equations above stop being adequate descriptions of plasma curves.
• Flip-flop kinetics in subcutaneous peptide absorption, and how to distinguish absorption-limited from elimination-limited profiles.
• Receptor desensitization and tachyphylaxis in GHSR, GLP-1R, and melanocortin receptor families — the pharmacodynamic side of the dosing-interval question.
• Bioanalytical methods (LC-MS/MS vs. ELISA) for measuring peptide plasma concentrations, including why cross-reactivity with endogenous analogs complicates interpretation.